1. Home
  2. NKSH vs TVGN Comparison

NKSH vs TVGN Comparison

Compare NKSH & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

N/A

Current Price

$33.65

Market Cap

185.2M

Sector

Finance

ML Signal

N/A

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

N/A

Current Price

$0.37

Market Cap

89.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NKSH
TVGN
Founded
1891
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Blank Checks
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
185.2M
89.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NKSH
TVGN
Price
$33.65
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
12.6K
1.4M
Earning Date
01-22-2026
11-14-2025
Dividend Yield
4.48%
N/A
EPS Growth
41.35
N/A
EPS
2.04
N/A
Revenue
$51,980,000.00
N/A
Revenue This Year
$2.95
N/A
Revenue Next Year
$9.97
N/A
P/E Ratio
$16.51
N/A
Revenue Growth
19.63
N/A
52 Week Low
$23.75
$0.37
52 Week High
$34.24
$1.92

Technical Indicators

Market Signals
Indicator
NKSH
TVGN
Relative Strength Index (RSI) 73.75 36.34
Support Level $29.79 $0.39
Resistance Level $34.24 $0.47
Average True Range (ATR) 0.86 0.04
MACD 0.42 0.00
Stochastic Oscillator 96.58 1.72

Price Performance

Historical Comparison
NKSH
TVGN

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Share on Social Networks: